| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Secukinumab |
| Brand | Cosentyx® |
| Indication | Alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. |
| Assessment Process | |
| Rapid review commissioned | 02/12/2015 |
| Rapid review completed | 15/12/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation not Recommended |
The HSE has approved reimbursement following confidential price negotiations.